This is new today.
Their test is no better or worse than PSA for prostate. Company needs to just build more credibility with Docs and FDA using more real world testing data on patients with incipient intestinal cancer...
DIY is the American way, all he way.
to get NDA from FDA by 2019/2020. Check it out.
and insurance companies to approve. I can see this device being used with other break-thru therapies.
If the answer is YES, then longs will do well.
at 95 the downside is very limited, and the risk/reward is therefore in your favor..
Financing is already in place. Risk/reward looks good here.
Solid scripts, pricing, Euro, Japan, share buyback all positives.
Load up and save for better days
No other biotech with solid earnings, low PE, dividend, big moat.
This will blow over.e
in negotiations with pharmacy benefit managers.
cash flow, current clinical trials , assessment of competition, finances. GILD knocks all these out of the park.
$118 next resistance. Short covering will make it happen.
GILD probably looking for proven phase 1,2 clinical efficacy /no side effects viral/oncology areas. Product(s) they can take to marketplace ASAP.
They now have deep pockets, the huge cash flow and research, marketing and sales teams in place to bring more amazing cures in the viral and oncology, etc. areas to the world stage.